Paeds SAQs · mental-behavioural-and-psychosomatic
Depressive disorders in children and adolescents — formative SAQs
Formative SAQs on the criteria-based diagnosis of paediatric depression, suicide-risk assessment, stepped care, fluoxetine as first-line SSRI, and the black-box warning used wisely.
On this page & tools
Target exams
SAQ 1 (10 marks)
A 14-year-old girl is brought by her mother after her grades fell from A to D over one term, she stopped seeing friends, sleeps poorly, feels worthless, and has begun cutting her forearms. She is irritable in the interview and says "everyone would be better off without me" but denies a specific plan. Her PHQ-9 is 17. There is no history of manic episodes, no substance use, and no medical symptoms. [4] [5]
- Give the most likely diagnosis with the criteria that support it, and list three differentials with discriminators. (3) [4]
- Outline your immediate suicide-risk assessment and safety plan. (4) [3]
- Describe the stepped-care treatment plan, naming the first-line therapy and the first-line drug if one is indicated. (3) [1] [2]
Model answer — SAQ 1
(1) Diagnosis and differentials (3). The picture fits major depressive disorder, moderate to severe — at least five symptoms for at least two weeks with impairment (depressed/irritable mood, anhedonia, sleep disturbance, worthlessness, fatigue, and suicidal ideation), and a PHQ-9 above the adolescent cut-point that triggers a full interview. Differentials: adjustment disorder (here the syndrome exceeds a proportionate stress reaction); bipolar depression (excluded by the absence of manic or hypomanic episodes — but re-screen); substance-induced or organic mood disorder (no substance use and no medical symptoms, but exclude with focused tests); anaemia or hypothyroidism as mimics (fatigue and low mood). [4] [5]
(2) Risk assessment and safety plan (4). Ask directly about suicidal ideation, plan, intent, and access to means (medication, sharp objects), and weigh protective factors (family, friends, future orientation). Document the assessment. Form a collaborative written safety plan: warning signs, internal coping strategies, trusted people and places, professional contacts, and means restriction (secure medications and sharp objects). Agree a clearly named clinician for follow-up within days, involve carers within the bounds of confidentiality and safety, and arrange same-day specialist review if intent or plan escalates. Asking directly does not increase risk. [3]
(3) Stepped care (3). Severity is moderate to severe, so specialist child and adolescent mental-health involvement is appropriate. First-line is evidence-based psychotherapy (CBT or IPT-A). Because of the severity and suicidality, add fluoxetine — the first-line SSRI in under-18s (Cipriani NMA; TADS) — starting low (e.g. fluoxetine 10 mg oral daily), reviewing at one week then about two weekly. Combination of fluoxetine with CBT is supported by TADS for severe presentations. Do not let the suicidality warning delay treatment; monitor carefully instead. [1] [2] [3]
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References7Show ledgerHide ledger
- [1]Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet, 2016.PMID 27289172
- [2]March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 2004.PMID 15315995
- [3]Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA, 2007.PMID 17440145
- [4]Zuckerbrot RA, Cheung AH, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management. Pediatrics, 2018.PMID 29483200
- [5]Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management. Pediatrics, 2018.PMID 29483201
- [6]Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA, 2008.PMID 18314433
- [7]Goodyer IM, Reynolds S, Barrett B, et al. Cognitive behavioural therapy and short-term psychoanalytical psychotherapy versus a brief psychosocial intervention in adolescents with unipolar major depressive disorder (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled superiority trial. Lancet Psychiatry, 2017.PMID 27914903